Autolus Therapeutics (AUTL) Return on Sales (2017 - 2025)

Autolus Therapeutics (AUTL) has 7 years of Return on Sales data on file, last reported at 0.04% in Q4 2025.

• For the quarter ending Q4 2025, Return on Sales rose 948.0% year-over-year to 0.04%; the trailing twelve-month figure through Dec 2025 stood at 0.04% (up 18.0% YoY), and the FY2025 full-year result was 0.04%, up 18.0% from the prior year.
• Return on Sales for Q4 2025 stood at 0.04%, roughly flat from 0.04% in the prior quarter.
• Across five years, Return on Sales topped out at 569.85% in Q2 2022 and bottomed at 1896.65% in Q3 2021.
• The 5-year median for Return on Sales is 0.29% (2024), against an average of 67.64%.
• The widest annual swing landed in 2021, when Return on Sales sank 189544 bps; it then surged 189791 bps in 2022.
• A 5-year view of Return on Sales shows it stood at 0.06% in 2021, then sank by 15836 bps to 8.97% in 2022, then jumped by 86 bps to 1.23% in 2023, then tumbled by 676 bps to 9.52% in 2024, then soared by 100 bps to 0.04% in 2025.
• The last three Return on Sales figures came in at 0.04% (Q4 2025), 0.04% (Q3 2025), and 0.02% (Q2 2025), per Business Quant data.

Peer Comparison